RxDoctor Payments Data

Jonathan Brugger, MD

Ophthalmology · Sarasota, FLNPI 1013172105

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.2%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Genentech USA, Inc. at 50.1% of the total. 2025 is the largest year on record at $6,029, 3.1 times the $1,972 reported in 2019. Among ophthalmology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$14,815in general payments, 2019–2025

Across 108 payments — averaging $137.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$7K
  • Regeneron$2K
  • Roche TCRC, Inc.$1K
  • Astellas Pharma US Inc$1K
  • Apellis Pharmaceuticals, Inc.$930
  • Alcon$444
  • plus $1K from 14 others
$16,414in research payments, 2019–2025

Across 428 payments — averaging $38.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Notal Vision, Inc.$16K
  • F. Hoffmann-la Roche AG$334

What the payments were for

  • Consulting fees$6,10541%
  • Speaking & faculty fees$5774%
  • Travel & lodging$3,25322%
  • Food & beverage$4,88033%

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,815 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida →

Medicare billing

Part B allowed, 2024
$2,473,657
Medicare patients
1,192
Services billed
47,884

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate113$4,092
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha228$2,483
Brimonidine Tartrate15$1,088
Ketorolac Tromethamine19$753
Latanoprost66$618
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat25$592
MoxifloxacinMoxifloxacin Hcl20$420
Dorzolamide Hcl13$291
Timolol Maleate14$54

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Sarasota

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →